References
- Rainer BM, Kang S, Chien AL. Rosacea: epidemiology, pathogenesis, and treatment. Dermatoendocrinology. 2017;9(1):e1361574.
- Buhl T, Sulk M, Nowak P, et al. Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1/Th17 pathways. J Invest Dermatol. 2015;135(9):2198–2208.
- Sharma A, Kroumpouzos G, Kassir M, et al. Rosacea management: a comprehensive review. J Cosmet Dermatol. 2022;21(5):1895–1904.
- Wilms EB, Touw DJ, Heijerman HGM. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis. Ther Drug Monit. 2006;28(2):219–225.
- Tateda K, Comte R, Pechere JC, et al. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2001;45(6):1930–1933.
- Pile HD, Sadiq NM. Isotretinoin. North Carolina, USA: StatPearls; 2021.
- Kim JH, Oh YS, Choi EH. Oral azithromycin for treatment of intractable rosacea. J Korean Med Sci. 2011;26(5):694–696.
- Bakar Ö, Demirçay Z, Yuksel M, et al. The effect of azithromycin on reactive oxygen species in rosacea. Clin Exp Dermatol. 2007;32(2):197–200.
- Jahns AC, Lundskog B, Ganceviciene R, et al. An increased incidence of Propionibacterium acnes biofilms in acne vulgaris: a case-control study. Br J Dermatol. 2012;167(1):50–58.